# Trials recruiting in Bosnia and Herzegovina: 25 (2026)

ClinicalTrials.gov lists 25 trials recruiting or not yet recruiting with a site in Bosnia and Herzegovina.

## The full list

Clinical trials recruiting in Bosnia and Herzegovina: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/bosnia-and-herzegovina

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07936240 | Comparison of the Inflammatory Response in Patients Undergoing Surgery for Degenerative Spinal Diseases: Sevoflurane-Based Balanced... | University Clinical Hospital Mostar | Phase 4 | Not yet recruiting | Degenerative Spinal Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936240) |
| October 21, 2026 | NCT07885891 | Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | Wockhardt | Phase 3 | Not yet recruiting | Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885891) |
| October 5, 2026 | NCT07858565 | Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of... | Bosnalijek D.D | Observational | Recruiting | Schizophrenia, Bipolar Affective Disorder | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858565) |
| September 17, 2026 | NCT07826819 | Consensus on Low-resource Setting Definition: An inteRnational Delphi sTudY (CLARITY-LRS) | University Clinical Centre of Republic of Srpska | Observational | Not yet recruiting | Resource-Limited Setting, Delphi Study, Consensus, Critical Care, Acute Care Medical, Global Health, Health Systems | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07826819) |
| August 12, 2026 | NCT07760688 | Structured Periprocedural Nursing Interventions in Men Undergoing Transrectal Prostate Biopsy | University of Mostar | Not applicable | Recruiting | Anxiety, Biopsy | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760688) |
| June 8, 2026 | NCT07633288 | A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With... | SynAct Pharma Aps | Phase 2 | Recruiting | Respiratory Viral Infection | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633288) |
| March 31, 2026 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative... | TG Therapeutics, Inc. | Phase 2 | Recruiting | Multiple Sclerosis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503873) |
| March 9, 2026 | NCT07458191 | Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation | Bosnalijek D.D | Observational | Recruiting | Nonvalvular Atrial Fibrillation | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458191) |
| December 24, 2025 | NCT07301736 | Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | Chiesi Farmaceutici S.p.A. | Phase 2 | Recruiting | Asthma | 780 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301736) |
| October 28, 2025 | NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated... | mAbxience Research S.L. | Phase 3 | Recruiting | Advanced (Unresectable or Metastatic) Melanoma | 632 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221734) |
| August 19, 2025 | NCT07130916 | A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Non-Small Cell Lung Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07130916) |
| June 24, 2025 | NCT07032662 | Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Immunovant Sciences GmbH | Phase 2 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07032662) |
| June 10, 2025 | NCT07012395 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | Spyre Therapeutics, Inc. | Phase 2 | Recruiting | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07012395) |
| April 9, 2025 | NCT06920030 | Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead | Berlin Heals GmbH | Not applicable | Recruiting | Idiopathic Cardiomyopathy, Left Ventricular (LV) Systolic Dysfunction, Non-ischemic Cardiomyopathy | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06920030) |
| December 24, 2024 | NCT06746233 | Drug-Eluting Balloon or Drug-Eluting Stent in Acute Myocardial Infarction: A Randomized Controlled Trial | Institute of Cardiovascular Diseases, Vojvodina | Not applicable | Recruiting | ST Elevation Myocardial Infarction (STEMI) | 598 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06746233) |
| October 17, 2024 | NCT06647069 | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases | Sanofi | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06647069) |
| September 19, 2024 | NCT06601270 | SCAD : a Registry of Spontaneous Coronary Artery Dissection | European Society of Cardiology | Observational | Recruiting | Spontaneous Coronary Artery Dissection | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06601270) |
| June 26, 2024 | NCT06475781 | Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward) | Foresee Pharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Group 3 Pulmonary Hypertension | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06475781) |
| January 26, 2024 | NCT06226883 | A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Phase 2 | Recruiting | Inflammatory Bowel Diseases, Crohn's Disease | 385 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226883) |
| February 17, 2023 | NCT05732701 | Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions | Insel Gruppe AG, University Hospital Bern | Not applicable | Recruiting | Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease | 2,788 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05732701) |
| December 9, 2022 | NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in... | Grifols Therapeutics LLC | Phase 3 | Recruiting | Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05645107) |
| October 20, 2022 | NCT05588323 | Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids | Shionogi | Phase 1/2 | Recruiting | Opioid-Induced Constipation (OIC) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05588323) |
| January 21, 2022 | NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | Can-Fite BioPharma | Phase 3 | Recruiting | Hepatocellular Carcinoma, Cirrhosis | 471 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05201404) |
| January 13, 2022 | NCT05189860 | The C-MIC-II Follow-Up Study | Berlin Heals GmbH | Not applicable | Recruiting | Systolic Left Ventricular Dysfunction | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05189860) |
| August 18, 2020 | NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 1 | Recruiting | Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04516447) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| University Clinical Centre of the Republic of Srpska | Banja Luka | 4 |
| University Clinical Hospital Mostar | Mostar | 2 |
| University Clinical Centre of the Republic of Srpska - Paprikovac\_Site n. 070004 | Banja Luka | 1 |
| Dr. Abdulah Nakas General Hospital\_Site n. 070007 | Sarajevo | 1 |
| Dr. Abdulah Nakas General Hospital\_Site n. 070009 | Sarajevo | 1 |
| University Clinical Hospital Mostar\_Site n. 07001 | Siroki Brijeg | 1 |
| University Clinical Centre Tuzla\_Site n. 070002 | Tuzla | 1 |
| University Clinical Center of the Republic of Srbska | Banja Luka | 1 |
| University Clinical Center of the Republic of Srpska | Banja Luka | 1 |
| Clinical Center of the University of Sarajevo | Sarajevo | 1 |
| Hospital Plava Medical Group | Tuzla | 1 |
| Cantonal Hospital Zenica, Department of Internal Medicine | Zenica | 1 |
| University Clinical Hospital , Mostar | Mostar | 1 |
| Republika Srpska University Clinical Centre of the Republic of Srpska, Dvanaest beba bb | Banja Luka | 1 |
| University Clinical Hospital Mosta, Bijeli Brijeg bb | Mostar | 1 |
| Clinical Center University of Sarajevo, Bolnicka 25 | Sarajevo | 1 |
| Cantonal Hospital Zenica, Crkvice 67 | Zenica | 1 |
| 841 University Clinical Centre of Republic of Srpska | Banja Luka | 1 |
| 843 University Clinical Hospital Mostar | Mostar | 1 |
| 842 University Clinical Centre Sarajevo | Sarajevo | 1 |
| University Clinical Centre of Republic of Srpska | Banja Luka | 1 |
| University Clinical Center of Sarajevo | Sarajevo | 1 |
| Clinic of Psychiatry, University Clinical Center of Sarajevo | Sarajevo | 1 |
| Clinic for diseases of the heart, blood vessels and rheumatism | Sarajevo | 1 |
| Clinical Center University of Sarajevo | Sarajevo | 1 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 5 |
| Observational | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Inflammatory Bowel Diseases | 2 |
| Asthma | 1 |
| Colitis, Ulcerative | 1 |
| Colitis | 1 |
| Cardiomyopathies | 1 |
| Cardiomyopathy, Dilated | 1 |
| Heart Failure | 1 |
| Coronary Artery Disease | 1 |
| Anxiety Disorders | 1 |
| Prostatic Neoplasms | 1 |
| Lower Urinary Tract Symptoms | 1 |
| Multiple Sclerosis | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
| Fallopian Tube Neoplasms | 1 |
| Crohn Disease | 1 |
| Agammaglobulinemia | 1 |
| Bacterial Infections | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Opioid-Induced Constipation | 1 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| ST Elevation Myocardial Infarction | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Arthritis, Rheumatoid | 1 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Berlin Heals GmbH | 2 |
| Bosnalijek D.D | 2 |
| [Chiesi Farmaceutici S.p.A.](https://specstream.ai/data/clinical-trials/company/chiesi-farmaceutici-s-p-a) | 1 |
| Spyre Therapeutics, Inc. | 1 |
| Insel Gruppe AG, University Hospital Bern | 1 |
| University of Mostar | 1 |
| [TG Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/tg-therapeutics-inc) | 1 |
| Foresee Pharmaceuticals Co., Ltd. | 1 |
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 1 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 1 |
| [Grifols Therapeutics LLC](https://specstream.ai/data/clinical-trials/company/grifols-therapeutics-llc) | 1 |
| [Shionogi](https://specstream.ai/data/clinical-trials/company/shionogi) | 1 |
| Immunovant Sciences GmbH | 1 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 1 |
| Institute of Cardiovascular Diseases, Vojvodina | 1 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 1 |
| [Can-Fite BioPharma](https://specstream.ai/data/clinical-trials/company/can-fite-biopharma) | 1 |
| mAbxience Research S.L. | 1 |
| University Clinical Centre of Republic of Srpska | 1 |
| University Clinical Hospital Mostar | 1 |
| European Society of Cardiology | 1 |
| SynAct Pharma Aps | 1 |
| [Wockhardt](https://specstream.ai/data/clinical-trials/company/wockhardt) | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Home insurance agencies in the United States](https://specstream.ai/data/businesses/home-insurance-agencies/united-states)
- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
- [Accounting firms in the United States](https://specstream.ai/data/businesses/accounting-firms/united-states)
- [Dental laboratories in the United States](https://specstream.ai/data/businesses/dental-laboratories/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Screen printers in the United States](https://specstream.ai/data/businesses/screen-printers/united-states)
